By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Edison Pharmaceuticals, Inc. 

5941 Optical Court, Suite 228

San Jose  California  95138  U.S.A.
Phone: 408-960-2910 Fax: 408-413-5300


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





Company News
FDA Grants Edison Pharmaceuticals, Inc.'s EPI-743 Orphan Status For Leigh Syndrome 6/9/2014 10:19:43 AM
Edison Pharmaceuticals, Inc.'s EPI-743 Granted Orphan Designation For Leigh Syndrome In Japan 5/21/2014 9:15:53 AM
FDA Grants Fast Track Status To Edison Pharmaceuticals, Inc.' EPI-743 For Friedreich's Ataxia 3/17/2014 9:48:00 AM
Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Pearson Syndrome Clinical Trial 3/17/2014 8:13:35 AM
Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co., Ltd. In Japan 3/10/2014 12:29:22 PM
FDA Grants Edison Pharmaceuticals, Inc.'s EPI-743 Orphan Status For Friedreich's Ataxia 2/4/2014 9:54:46 AM
Edison Pharmaceuticals, Inc., Dainippon Sumitomo Pharma Co., Ltd. Ink "Biological Energy" Pact Worth $4.3 Billion 1/31/2014 6:48:05 AM
Edison Pharmaceuticals, Inc., FARA, and University of South Florida Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations 11/4/2013 9:20:12 AM
Edison Pharmaceuticals, Inc. Announces Initiation of National Institutes of Health (NIH)-Sponsored EPI-743 Clinical Trial With NIH Undiagnosed Diseases Program Patients 9/24/2013 10:52:03 AM
Edison Pharmaceuticals, Inc. Signs Licensing Agreement With Dainippon Sumitomo Pharma Co., Ltd. for Up to $545 Million 3/28/2013 7:35:41 AM
1234
//-->